Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.49 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 11/20 | 0.47 |
| ▸ | RAF1 | P04049 | 8/20 | 0.47 |
| ▸ | CSF1R | P07333 | 6/20 | 0.47 |
| ▸ | LYN | P07948 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | HCK | P08631 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072018 | 0.94 | TNK2 (0.56) | SYKTNK2MAP4K2BRAFRAF1 | |
| SCHEMBL10072030 | 0.92 | SYK (0.48) | SYKTNK2MAP4K2BRAFRAF1 | |
| SCHEMBL502168 | 0.90 | SYK (0.51) | SYKTNK2MAP4K2BRAFRAF1 | |
| SCHEMBL502521 | 0.89 | BRAF (0.61) | SYKTNK2MAP4K2BRAFRAF1 | |
| SCHEMBL10072015 | 0.88 | BRAF (0.53) | SYKTNK2MAP4K2BRAFRAF1 | |
| SCHEMBL10072021 | 0.87 | SYK (0.59) | SYKBRAFRAF1LCKKDR | |
| SCHEMBL10043949 | 0.86 | CSF1R (0.55) | SYKTNK2MAP4K2BRAFRAF1 | |
| SCHEMBL10072020 | 0.86 | SYK (0.48) | SYKTNK2MAP4K2BRAFRAF1 | |
| SCHEMBL10072031 | 0.86 | SYK (0.47) | SYKTNK2MAP4K2BRAFRAF1 | |
| SCHEMBL10071751 | 0.84 | CSF1R (0.51) | SYKTNK2MAP4K2BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2010-04-01 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | SYK 42/4885TNK2 79/4885MAP4K2 17/4885 |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | SYK 42/4885TNK2 79/4885MAP4K2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.